10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Ipsen shares began trading around 2% higher on Thursday morning, after the French biotech announced today it would restart the global Phase III MOVE trial, in people over the age of 14. 26 March 2020
Sino-America immuno-oncology biotech firm BeiGene today announced that, on March 25, 2020, the China National Medical Products Administration (NMPA) suspended the importation, sales and use of Abraxane (nanoparticle albumin-bound paclitaxel) in China supplied to BeiGene by Celgene, now a Bristol-Myers Squibb company. 25 March 2020
Danish CNS specialist Lundbeck has published positive data from the Phase III PROMISE 2 trial in Neurology, the medical journal of the American Academy of Neurology. 25 March 2020
US biotech Forge Therapeutics has entered into a research collaboration and option agreement with Swiss pharma giant Roche to license FG-LpxC LUNG, a novel antibiotic for the treatment of serious lung infections attributed to antibiotic-resistant Gram-negative bacteria including Pseudomonas aeruginosa. 25 March 2020
German biotechnology firm Sartorius has supported CanSino Biologics and Major General Chen Wei’s team at the Institute of Bioengineering at the Academy of Military Medical Sciences in China in their development of the first vaccine candidate against the novel coronavirus SARS-CoV-2 to enter clinical trials. 25 March 2020
Ono Pharmaceutical has received manufacturing and marketing approval for Velexbru (tirabrutinib) tablet 80mg, a Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of recurrent or refractory primary central nervous system lymphoma, in Japan. 25 March 2020
Netherlands-based Norgine says it has acquired Azanta, a Denmark-based specialty biopharmaceutical company operating within women’s healthcare, addiction medicine and oncology. Azanta becomes a wholly-owned subsidiary of Norgine. 25 March 2020
The Ghent, Belgium-based Flanders Interuniversity Institute for Biotechnology (VIB) is to conduct a trial, together with the University Hospital Ghent, to test Leukine (sargramostim) against respiratory illness caused by COVID-19. 25 March 2020
UK novel RNA therapeutics specialist Silence Therapeutics saw its sales rocket 32% to 535.00 pence as markets opened today, as it announced a strategic collaboration with AstraZeneca to discover, develop and commercialize small interfering RNA (siRNA) therapeutics for cardiovascular, renal, metabolic and respiratory diseases. 25 March 2020
As the world watches aghast, the novel coronavirus continues to spread its tentacles around the globe, with cases of COVID-19 rising to nearly 375,000 on Tuesday, an increase of 75,000 from the day before. 25 March 2020
Austro-American company CEL-SCI Corporation and the University of Georgia’s (UGA) Center for Vaccines and Immunology have announced a collaboration in COVID-19. 24 March 2020
Stock in Novavax rose more than 15% by early afternoon on Tuesday, after the US vaccine developer announced positive data for a Phase III clinical trial of NanoFlu. 24 March 2020
Due to overwhelming demand, US biotech giant Gilead Sciences is temporarily stopping compassionate-use of its remdesivir, in order to focus supplies of the investigational antiviral for clinical testing as a possible treatment for the new coronavirus, COVID-19. 24 March 2020
Belgian mRNA company eTheRNA Immunotherapies has announced that a consortium has been formed with North American and European partners to develop a vaccine against SARS-CoV-2 and preclinical development has started. 24 March 2020
Ireland-headquartered Ovoca Bio saw its shares gain more than 7% to 7.50 pence, after it announced an agreement to acquire the remaining shareholding in Russian biotech firm IVIX that the company does not already control. 24 March 2020
Boston, USA-based biotech Pieris Pharmaceuticals has announced that its immuno-oncology collaboration with independent French drugmaker Servier is now to be focused on the two most advanced programs. 24 March 2020
Data published at a virtual Clinical Trial Session, conducted by the Muscular Dystrophy Association (MDA), show Zolgensma (onasemnogene abeparvovec-xioi) produced significant benefit to people with spinal muscular atrophy (SMA). 24 March 2020
South Korea's Celltrion Healthcare on Monday announced key milestones in its efforts to fight the 2019 novel coronavirus (COVID-19) pandemic. 24 March 2020